Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination therapy for type 2 diabetes.

S Mudaliar1, R R Henry

  • 1University of California at San Diego, VA Medical Center, San Diego, California, USA.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
|July 15, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatobiliary and Pancreatic: Kasabach-Merritt syndrome in adult.

Journal of gastroenterology and hepatology·2019
Same author

Editorial: putting more muscle into treating our chronic hepatitis B patients-the importance of assessing sarcopenia.

Alimentary pharmacology & therapeutics·2018
Same author

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.

Diabetes & metabolism·2017
Same author

Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.

Diabetes, obesity & metabolism·2016
Same author

AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes.

Diabetes, obesity & metabolism·2015
Same author

Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes.

Diabetes, obesity & metabolism·2015
Same journal

Tirzepatide versus conventional GLP-1 receptor agonists for treatment simplification in type 2 diabetes mellitus: a real-world study.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
Same journal

Risk-stratification of pediatric thyroid nodules using ATA and ACR TIRADS adult thyroid nodule scoring systems.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
Same journal

Effectiveness of GLP-1 receptor agonists and SGLT-2 inhibitors combination therapy in type 2 diabetes: a real world experience.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
Same journal

North American Society for Interventional Thyroidology (NASIT) Statement on Directed Ablative Therapy for the Management of of Low Risk Papillary Thyroid Carcinoma.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
Same journal

Lower Cutoffs Improve the Diagnostic Performance of DDAVP-Stimulated Bilateral Inferior Petrosal Sinus Sampling for Cushing Disease: A Prospective Cohort Study.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
Same journal

Efficacy of Initiation of Semaglutide versus SGLT2 inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multicenter Propensity-Matched Real-World Study.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
See all related articles

Combination therapy improves glycemic control in type 2 diabetes mellitus. Oral antidiabetic agents can delay or reduce the need for insulin, enhancing treatment outcomes.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus (T2DM) management requires optimal glycemic control to prevent complications.
  • Diet and exercise are foundational, but pharmacologic intervention is often necessary.
  • Sulfonylureas have been a traditional first-line oral therapy, but their efficacy wanes over time.

Purpose of the Study:

  • To explore a rational approach for enhancing glycemic control in T2DM using combination therapy.
  • To review the role of various antidiabetic agents and their combinations in T2DM management.

Main Methods:

  • Review of existing literature on antidiabetic agents and their mechanisms of action.
  • Analysis of clinical studies evaluating monotherapy and combination therapy in T2DM.

Related Experiment Videos

Main Results:

  • Pharmacologic agents are crucial for achieving glycemic targets and reducing micro/macrovascular complications in T2DM.
  • Combination therapy with oral agents can optimize glycemic control, potentially delaying insulin initiation or intensification.
  • In some cases, oral combination therapy may allow for discontinuation of insulin in favor of oral agents.

Conclusions:

  • Four classes of oral antidiabetic agents are available: insulin secretagogues, biguanides, alpha-glucosidase inhibitors, and thiazolidinediones.
  • Combination therapy leverages diverse mechanisms of action to improve glycemic control when monotherapy or insulin is insufficient.
  • Further research is ongoing to refine and optimize combination treatment strategies for T2DM.